Drug Approval | June 12, 2022
China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Tislelizumab is now approved in nine indications in China
Tislelizumab is now approved in nine indications in China
Plans to establish six state of the art TaCa Centre for Surgery in next 2 years in these states
Based on a post hoc analysis, fewer required respiratory interventions
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
The rally attracted around 250 riders, including professionals and amateurs.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Subscribe To Our Newsletter & Stay Updated
